{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:51:07Z","timestamp":1790661067179,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The study aims to identify the drugs associated with drug withdrawal syndrome in the Food and Drug Administration Adverse Event Reporting System (FAERS) and estimate their risks of causing withdrawal syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All the data were collected from FAERS from the first quarter of 2004 to the third quarter of 2023. Disproportionality analyses of odds ratio (ROR) and proportional reported ratio were conducted to identify potential adverse effects signal of drug withdrawal syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 94,370 reports related to withdrawal syndrome from the data. The top 50 drugs with most frequency reported were analyzed, and 29 exhibited a positive signal based on the number of reports. The top three categories of drugs with positive signals included opioids, antidepressant drugs and antianxiety drugs. Other classifications included opioid antagonist, muscle relaxant, antiepileptic drugs, analgesics, hypnotic sedative drugs and antipsychotic drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our analysis of FAERS data yielded a comprehensive list of drugs associated with withdrawal syndrome. This information is vital for healthcare professionals, including doctors and pharmacists, as it aids in better recognition and management of withdrawal symptoms in patients undergoing treatment with these medications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1385651","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T05:06:40Z","timestamp":1720588000000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Zheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianzhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40360-023-00657-y","article-title":"Medication-induced osteonecrosis of the jaw: a review of cases from the Food and drug administration adverse event reporting system (FAERS)","volume":"24","author":"Ahdi","year":"2023","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.18773\/austprescr.2023.025","article-title":"Gabapentinoids: a therapeutic review","volume":"46","author":"Athavale","year":"2023","journal-title":"Aust. Prescr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"CD011481","DOI":"10.1002\/14651858.cd011481.pub2","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"2018","author":"Baandrup","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.rcpeng.2021.06.013","article-title":"Zolpidem dependence and withdrawal. A case report of generalized seizures","volume":"52","author":"Barbosa Eyler","year":"2023","journal-title":"Rev. Colomb. Psiquiatr. Engl. Ed."},{"key":"B5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.24869\/psyd.2018.142","article-title":"On the addictive power of gabapentinoids: a mini-review","volume":"30","author":"Bonnet","year":"2018","journal-title":"Psychiatr. Danub"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review","volume":"27","author":"Bonnet","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for chronic noncancer pain: a systematic review and meta-analysis","volume":"320","author":"Busse","year":"2018","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"bcr2014204322","DOI":"10.1136\/bcr-2014-204322","article-title":"Cardiac arrest due to baclofen withdrawal syndrome","volume":"14","author":"Cardoso","year":"2014","journal-title":"Case Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1176\/ps.2006.57.8.1094","article-title":"Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial","volume":"57","author":"Chakos","year":"2006","journal-title":"Psychiatr. Serv."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1097\/phm.0000000000000665","article-title":"Transdermal scopolamine withdrawal syndrome case report in the pediatric cerebral palsy population","volume":"96","author":"Chowdhury","year":"2017","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.3390\/molecules28134969","article-title":"Understanding the mechanisms of action and effects of drugs of abuse","volume":"28","author":"Ciuca Anghel","year":"2023","journal-title":"Molecules"},{"key":"B12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJMp1706754","article-title":"Cyberattack on britain's national health service - a wake-up call for modern medicine","volume":"377","author":"Clarke","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1053\/apmr.2002.32820","article-title":"Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome","volume":"83","author":"Coffey","year":"2002","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"B14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.addbeh.2018.08.027","article-title":"A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based?","volume":"97","author":"Davies","year":"2019","journal-title":"Addict. Behav."},{"key":"B15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000491524","article-title":"Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review","volume":"87","author":"Fava","year":"2018","journal-title":"Psychother. Psychosom."},{"key":"B16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000370338","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review","volume":"84","author":"Fava","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"B17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/nmd.0b013e3182a2168a","article-title":"Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility","volume":"201","author":"First","year":"2013","journal-title":"Clin. Util. J. Nerv. Ment. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s40264-022-01246-4","article-title":"Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database","volume":"45","author":"Gastaldon","year":"2022","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2165\/00002018-200124030-00003","article-title":"Antidepressant discontinuation syndromes","volume":"24","author":"Haddad","year":"2001","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e19926","DOI":"10.5812\/ircmj.19926","article-title":"Zolpidem dependency and withdrawal seizure: a case report study","volume":"16","author":"Haji Seyed Javadi","year":"2014","journal-title":"Iran. Red. Crescent Med. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3238\/arztebl.2019.0355","article-title":"Antidepressant withdrawal and rebound phenomena","volume":"116","author":"Henssler","year":"2019","journal-title":"Dtsch. Arztebl Int."},{"key":"B24","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/B978-032303004-5.50187-3","article-title":"Chapter 183 - withdrawal syndromes","volume-title":"Comprehensive pediatric hospital medicine","author":"Hoffman Rj","year":"2007"},{"key":"B25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/comp.2002.35910","article-title":"Comorbidity of substance abuse and other psychiatric disorders in acute general psychiatric admissions: a study from Lebanon","volume":"43","author":"Karam","year":"2002","journal-title":"Compr. Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.addbeh.2011.09.010","article-title":"Treatment of substance abusing patients with comorbid psychiatric disorders","volume":"37","author":"Kelly","year":"2012","journal-title":"Addict. Behav."},{"key":"B27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.pnpbp.2011.11.008","article-title":"Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic","volume":"36","author":"Kitajima","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","article-title":"Benzodiazepine harm: how can it be reduced?","volume":"77","author":"Lader","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1310\/hpj4903-218","article-title":"Scopolamine patch withdrawal syndrome","volume":"49","author":"Lau","year":"2014","journal-title":"Hosp. Pharm."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/0028-3908(87)90112-2","article-title":"Buprenorphine has potent kappa opioid receptor antagonist activity","volume":"26","author":"Leander","year":"1987","journal-title":"Neuropharmacology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1259611","DOI":"10.3389\/fphar.2023.1259611","article-title":"Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1517\/14656560903213405","article-title":"The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence","volume":"10","author":"Mammen","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/00952990.2023.2248646","article-title":"Prevalence and correlates of DSM-5 opioid withdrawal syndrome in U.S. adults with non-medical use of prescription opioids: results from a national sample","volume":"49","author":"Mannes","year":"2023","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"B34","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S2215-0366(19)30331-1","article-title":"Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England","volume":"6","author":"Marsden","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1176\/ajp.148.4.517","article-title":"Controlled discontinuation of benzodiazepine treatment for patients with panic disorder","volume":"148","author":"Noyes","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/brainsci8040073","article-title":"Abuse of prescription drugs in the context of novel psychoactive substances (NPS): a systematic review","volume":"8","author":"Schifano","year":"2018","journal-title":"Brain Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jurban\/79.2.266","article-title":"Drug users' involvement in the drug economy: implications for harm reduction and HIV prevention programs","volume":"79","author":"Sherman","year":"2002","journal-title":"J. Urban Health Bull. N. Y. Acad. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jad.2022.08.011","article-title":"Description of antidepressant withdrawal symptoms in clinical practice guidelines on depression: a systematic review","volume":"316","author":"Sorensen","year":"2022","journal-title":"J. Affect Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(20)30852-7","article-title":"New directions in the treatment of opioid withdrawal","volume":"395","author":"Srivastava","year":"2020","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1111\/add.15818","article-title":"Clinical management of opioid withdrawal","volume":"117","author":"Torres-Lockhart","year":"2022","journal-title":"Addiction"},{"key":"B43","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.drugalcdep.2019.107709","article-title":"Gabapentin drug misuse signals: a pharmacovigilance assessment using the FDA adverse event reporting system","volume":"206","author":"Vickers-Smith","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"B44","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain--misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/1742-6723.13624","article-title":"Hyoscine patch withdrawal syndrome in a returned traveller","volume":"32","author":"Wahl","year":"2020","journal-title":"Emerg. Med. Australas."},{"key":"B47","first-page":"76","article-title":"Zolpidem dependence and withdrawal seizure--report of two cases","volume":"23","author":"Wang","year":"2011","journal-title":"Psychiatr. Danub"},{"key":"B48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jsat.2014.03.004","article-title":"Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain","volume":"47","author":"Weiss","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"B49","doi-asserted-by":"publisher","first-page":"CD012592","DOI":"10.1002\/14651858.CD012592.pub2","article-title":"Opioids for cancer pain - an overview of Cochrane reviews","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1044744","DOI":"10.3389\/fphar.2022.1044744","article-title":"Drug-induced fall risk in older patients: a pharmacovigilance study of FDA adverse event reporting system database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40360-023-00702-w","article-title":"A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)","volume":"24","author":"Zou","year":"2023","journal-title":"BMC Pharmacol. Toxicol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1385651\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T05:06:46Z","timestamp":1720588006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1385651\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":51,"alternative-id":["10.3389\/fphar.2024.1385651"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1385651","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"article-number":"1385651"}}